U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. For Industry
  3. Medical products for rare diseases and conditions
  4. Designating an Orphan Product: Drugs and Biological Products
  5. Orphan Drug Regulations-Proposed Rule
  1. Designating an Orphan Product: Drugs and Biological Products

Orphan Drug Regulations-Proposed Rule

The Food and Drug Administration (FDA) is proposing to amend the 1992 Orphan Drug Regulations issued to implement the Orphan Drug Act. These amendments are intended to clarify regulatory provisions and make minor improvements to address issues that have arisen since those regulations were issued.

Orphan Drug Regulations-Proposed Rule:
Docket No. FDA-2011-N-0583]
RIN 0910-AG72

The period to provide comments to the Orphan Drug Regulations-Proposed Rule closed on January 17, 2012. Public submission comments to the Orphan Drug Regulations-Proposed Rule may be viewed at www.regulations.gov by searching the Docket No. FDA-2011-N-0583. The FDA is currently reviewing the comments.

For questions regarding the proposed rule contact:

Ms. Erica K McNeilly
301-796-8679
erica.mcneilly@fda.hhs.gov

Back to Top